Trial | NCT00042497  Report issue

Title

Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Suspended

  • Study Participants

    60
The objective is to determine the safety and efficacy of dexosome immunotherapy in patients with Stage IV malignant melanoma
Study Started
Jul 31
2002
Last Update
Jun 24
2005
Estimate

Biological autologous dexosomes loaded with tumor-specific peptides

Criteria 

Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic disease.
All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35.
Patients must have adequate organ function and an estimated life expectancy of at least 3 months.
No Results Posted